Ástralía - enska - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - phenytoin, quantity: 6 mg/ml - oral liquid, suspension - excipient ingredients: sodium benzoate; polysorbate 40; citric acid monohydrate; glycerol; purified water; carmellose sodium; ethanol; vanillin; carmoisine; sucrose; sunset yellow fcf; aluminium magnesium silicate; flavour - dilantin is indicated for the control of grand mal and psychomotor seizures. dilantin will prevent or effectively decrease the incidence and severity of convulsive seizures in a high percentage of cases, with patients exhibiting little tendency to become resistant to its action. besides its effectiveness in controlling seizures, dilantin frequently improves the mental condition and outlook of epileptic patients and there is also increasing evidence that dilantin is valuable in the prevention of seizures occurring during or after neurosurgery and in the treatment of certain cardiac arrythmias. phenytoin serum level determinations may be necessary for optimal dosage adjustments (see dosage and administration).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

iotech pty ltd - sodium amidotrizoate, quantity: 370.5 mg/ml - oral liquid, solution - excipient ingredients: sorbitol; acesulfame potassium; quinoline yellow; methyl hydroxybenzoate; citric acid; purified water; flavour - ioscan is a contrast medium for computerised axial tomograpghy examination of the gastrointestinal tract. it should be made up with water prior to use, and administered orally. it is indicated primarily for use when barium sulphate is not appropriate.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

integria healthcare australia pty ltd - angelica polymorpha, quantity: 300 microlitre/ml (equivalent: angelica polymorpha, qty 150 mg/ml); capsella bursa-pastoris, quantity: 250 microlitre/ml (equivalent: capsella bursa-pastoris, qty 125 mg/ml); paeonia lactiflora, quantity: 200 microlitre/ml (equivalent: paeonia lactiflora, qty 100 mg/ml); chamaelirium luteum, quantity: 250 microlitre/ml (equivalent: chamaelirium luteum, qty 125 mg/ml) - oral liquid - excipient ingredients: purified water - this formula contains herbs with uterine tonic activity.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - risperidone, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: purified water; benzoic acid; tartaric acid; sodium hydroxide - risperdal is indicated for the treatment of schizophrenia and related psychoses. risperdal is indicated for the short term treatment of acute mania associated with bipolar 1 disorder. risperdal is also indicated for the treatment of behavioural disturbances in dementia. risperdal is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent (see clinical trials for maintenance data). risperdal is indicated for the treatment of behavioural disorders associated with autism in children and adolescents (see clinical trials).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

nova sante pacific (international) pty ltd - ferric pyrophosphate, quantity: 125 microgram/ml (equivalent: iron, qty 26.25 microgram/ml); magnesium chloride hexahydrate, quantity: 800 microgram/ml (equivalent: magnesium, qty 96 microgram/ml); calcium glycerophosphate, quantity: 800 microgram/ml (equivalent: calcium, qty 128 microgram/ml); equisetum arvense, quantity: 1.3 mg/ml (equivalent: equisetum arvense, qty 5.2 mg/ml); taraxacum officinale, quantity: 650 microgram/ml (equivalent: taraxacum officinale, qty 2.6 mg/ml); panax ginseng, quantity: 3.22 - oral liquid, suspension - excipient ingredients: royal jelly; citric acid; glycerol; xanthan gum; carmellose; propyl hydroxybenzoate; benzoic acid; purified water; maize starch; ascorbyl palmitate; gelatin; dl-alpha-tocopherol; sucrose; vegetable oil; flavour - a herbal, mineral and vitamin supplement that acts as a health tonic and for the elimination of waste products from the body. vitamins can only be of assistance if dietry vitamin intake is inadequate.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - risperidone, quantity: 1 mg/ml - oral liquid, solution - excipient ingredients: tartaric acid; benzoic acid; purified water; hydrochloric acid - rixadone is indicated for the treatment of schizophrenia and related psychoses.,rixadone is indicated for the short-term treatment of acute mania associated with bipolar 1 disorder.,rixadone is indicated for the treatment (up to 12 weeks) of psychotic symptoms, or persistent agitation or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type.,rixadone is indicated in the treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (e.g. aggression, impulsivity and self-injurious behaviours) are prominent.,rixadone is indicated for the treatment of behavioural disorders associated with autism in children and adolescents.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

ucb australia pty ltd t/a ucb pharma division of ucb australia - levetiracetam, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: acesulfame potassium; purified water; maltitol solution; methyl hydroxybenzoate; ammonium glycyrrhizinate; citric acid monohydrate; propyl hydroxybenzoate; sodium citrate dihydrate; glycerol; flavour - keppra (film coated tablets and oral solution) is indicated for - use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation, - monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. - add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme), and - add on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige). keppra concentrate solution for iv infusion after dilution is an alternative for patients when oral administration is temporarily not feasible.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - levetiracetam, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: maltitol solution; purified water; citric acid monohydrate; glycerol; methyl hydroxybenzoate; propylene glycol; sodium citrate dihydrate; acesulfame potassium; propyl hydroxybenzoate; ammonium glycyrrhizinate; flavour - use in epileptic patients aged 4 years and older, initially as add on therapy, in the treatment of partial onset seizures with or without secondary generalisation; monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy; add on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme); and add on therapy in the treatment of primary generalized tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalized epilepsy (ige).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - caffeine, quantity: 12.5 mg - oral liquid, solution - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; water for injections - cafnea oral solution is indicated for the short-term treatment of apnoea of prematurity in infants between 28 and 33 weeks gestational age.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

integria healthcare australia pty ltd - taraxacum officinale, quantity: 200 microlitre/ml (equivalent: taraxacum officinale, qty 100 mg/ml); echinacea angustifolia, quantity: 200 microlitre/ml (equivalent: echinacea angustifolia, qty 100 mg/ml); silybum marianum, quantity: 200 microlitre/ml (equivalent: silybum marianum, qty 200 mg/ml); gentiana lutea, quantity: 40 microlitre/ml (equivalent: gentiana lutea, qty 20 mg/ml); matricaria chamomilla, quantity: 300 microlitre/ml (equivalent: matricaria chamomilla, qty 150 mg/ml) - oral liquid - excipient ingredients: purified water - used in traditional western herbal medicine as a digestive tonic and bitter to help stimulate appetite and aid digestion, as a cholagogue to help increase bile flow and to help relieve digestive disturbances/dyspepsia (such as nausea, heartburn, acidity, pain or discomfort, wind, fullness or belching)